Showing results (31-40 of 59) with videos related to
Sort By:
Pageof 6
Clinical Lung Cancer|September 24, 2014
Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancerMichael P Chu, Sunita Ghosh, Carole R Chambers, et al.Lung Cancer (Amsterdam, Netherlands)|August 6, 2021
The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancerBarbara Melosky, Paul Wheatley-Price, Rosalyn A Juergens, et al.Journal of Cachexia, Sarcopenia and Muscle|July 12, 2019
Rapid atrophy of cardiac left ventricular mass in patients with non-small cell carcinoma of the lungSeyyed Mohammad Reza Kazemi-Bajestani, Harald Becher, Charles Butts, et al.Current Oncology (Toronto, Ont.)|December 22, 2023
Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi ProcessJames Tankel, Jonathan Spicer, Quincy Chu, et al.Clinical Pharmacology in Drug Development|May 4, 2016
Effect of lapatinib on oral digoxin absorption in patientsKevin M Koch, Deborah A Smith, Jeff Botbyl, et al.Cancer Chemotherapy and Pharmacology|November 8, 2011
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancerHeather A Wakelee, Chris H Takimoto, Arturo Lopez-Anaya, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 25, 2016
A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207Paul Wheatley-Price, Quincy Chu, Maria Bonomi, et al.Current Oncology (Toronto, Ont.)|July 28, 2023
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World ExperienceMartin Rupp, Fiorella Fanton-Aita, Stephanie Snow, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung CancerBarbara Melosky, Helen Anderson, Ronald L Burkes, et al.Current Oncology (Toronto, Ont.)|October 22, 2021
Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy DatabaseHeidi A I Grosjean, Samantha Dolter, Daniel E Meyers, et al.Pageof 6